Agios Pharmaceuticals, Inc.
AGIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. The $1.70B market capitalization puts AGIO squarely in small-cap range for its industry. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Market Cap
$1.70B
Beta
0.58
P/E (TTM)
—
P/E (Fwd)
-6.22
EPS (TTM)
$-7.26
EPS (Fwd)
$-4.60
ROE
-32.8%
ROA
-21.7%
Cash
$737.0M
Total Debt
$35.7M
Free CF
-$267.2M
52W Change
-10.1%
Annual Financials
Cash vs Debt
With $737.0M in cash and $35.7M in debt, AGIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$267.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -32.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $14.2M (2022) to $54.0M (2025), reflecting a 279% increase over the period.
With a beta below 0.7, Agios Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, AGIO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AGIO.